ESMO Open
Publisher: Elsevier · ISSN 2059-7029 · 38 articles
- Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial
- Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer
- “Our patients deserve better”—roadblocks to optimal care in biliary malignancies
- Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measure
- Phase II study of magrolimab combination therapies in patients with advanced triple-negative breast cancer☆
- Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial☆
- Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results
- APOBEC3-mediated therapy resistance and immunogenicity in solid tumors: from genomic scars to therapeutic vulnerabilities